Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Market Closed 12-19 16:00:00 EST

83.76

+2.22

+2.72%

盘后83.76

+0.000.00%

18:28 EST

High85.34	Low81.26	Vol2.27M
Open82.51	D1 Closing81.54	Amplitude5.00%
Mkt Cap8.81B	Tradable Cap7.28B	Total Shares105.19M
T/O190.34M	T/O Rate2.61%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":83.76,"timestamp":1766178000000,"preClose":81.54,"halted":0,"volume":2270290,"hourTrading":{"tag":"盘后","latestPrice":83.76,"preClose":83.76,"latestTime":"18:28 EST","volume":164968,"amount":13817708.217626,"timestamp":1766186923661},"delay":0,"floatShares":86875270,"shares":105188217,"eps":0.873455,"marketStatus":"Market Closed","change":2.22,"latestTime":"12-19 16:00:00 EST","open":82.51,"high":85.34,"low":81.26,"amount":190339365.4767,"amplitude":0.050037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.873455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":81.54,"preHourTrading":{"tag":"盘前","latestPrice":81.55,"preClose":81.54,"latestTime":"09:27 EST","volume":996,"amount":81594.22236,"timestamp":1766154470001},"postHourTrading":{"tag":"盘后","latestPrice":83.76,"preClose":83.76,"latestTime":"18:28 EST","volume":164968,"amount":13817708.217626,"timestamp":1766186923661},"volumeRatio":1.643614836282847,"impliedVol":1.2334,"impliedVolPercentile":0.968},"requestUrl":"/m/hq/s/CORT/tweets","defaultTab":"tweets","newsList":[{"id":"2592119705","title":"These Stock Funds Are Cruising. Their 2026 Picks. -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2592119705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592119705?lang=en_us&edition=fundamental","pubTime":"2025-12-20 10:30","pubTimestamp":1766197800,"startTime":"0","endTime":"0","summary":"These market-beating funds see bargains in stocks like AppLovin, Wells Fargo, and Boeing. Where they're investing for the new year. By Ian Salisbury. It isn't easy for stock fund managers to beat the market. When they do, you might want to listen to what they say.With the S&P 500 index up 16% in 2025, keeping pace has been difficult for funds that didn't own large helpings of stocks leading the charge: tech giants like Nvidia, Broadcom, and Alphabet.Yet a handful of funds are beating the market. And some of the winning managers have found ways to thrive beyond tech, emphasizing stocks in sectors such as industrials, materials, and healthcare.Barron's recently connected with three fund managers who delivered some of the best returns this year, through Nov. 30. We wanted to find out how they did it and, more importantly, where they see bargains for 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","IE00B7SZLL34.SGD","LU2063271972.USD","LU0310800965.SGD","LU0154236417.USD","LU2361044865.SGD","LU1559883803.SGD","LU1435385759.SGD","LU2250418816.HKD","LU1861215975.USD","LU2065169927.USD","LU1852331112.SGD","GE","LU2294711713.HKD","LU1267930490.SGD","LU0957808578.USD","LU0320765489.SGD","LU0971096721.USD","LU2087625088.SGD","LU2290526834.HKD","LU2357125470.USD","LU1201861249.SGD","LU2098885051.SGD","LU2461242641.AUD","LU1093756168.USD","BK4608","LU0029864427.USD","LU0868494708.USD","LU1363072403.SGD","BK4551","LU1429558221.USD","LU0353189763.USD","LU0251142724.SGD","LU2065171311.SGD","BK4585","LU0130517989.USD","LU2249611893.SGD","LU2361045086.USD","LU0081259029.USD","LU0742534661.SGD","LU2506951792.HKD","LU0208291251.USD","LU1074936037.SGD","LU0072461881.USD","BK4516","LU2236285917.USD","LU0417517546.SGD","LU1791807156.HKD","LU2065171402.SGD","LU0006061336.USD","LU1815336760.USD","LU0128525689.USD","LU0708994859.HKD","BK4559","LU0444973449.USD","LU0149725797.USD","LU1303367103.USD","LU0823414478.USD","IE00B19Z9P08.USD","LU2264538146.SGD","LU0124384867.USD","IE0004091025.USD","LU2326559502.SGD","LU0211327993.USD","LU0683600562.USD","BK4170","IE0004086264.USD","LU0640476718.USD","LU0823414551.USD","LU1035773651.USD","BK4007","LU0289960550.SGD","LU1267930227.SGD","LU0353189680.USD","BK4023","IE00B19Z9Z06.USD","LU0097036916.USD","BK4588","BK4532","LU0211328371.USD","LU0128525929.USD","BAC","LU0444971666.USD","LU1814569148.SGD","UAMY","LU1978683503.SGD","LU2298322129.HKD","GB00BDT5M118.USD","IE00B19Z3B42.SGD","LU2361044949.HKD","LU1046421795.USD","BK4187","LU1280957306.USD","LU0476273544.USD","LU0162691827.USD","LU0477156953.USD","LU0052756011.USD","LU0175139822.USD","LU1064131342.USD","LU2360107168.USD","LU0130102774.USD","LU0787776722.HKD","IE0002270589.USD","IE00B19Z3581.USD","LU0267386448.USD","LU0310799852.SGD","BK4512","BK4504","LU0980610538.SGD","LU1642822529.SGD","LU0942090050.USD","APP","BK4539","LU2360106780.USD","BK4207","LU0070302665.USD","BA","LU0724618433.USD","LU1823568750.SGD","LU2065170008.USD","LU0314106906.USD","LU1668664300.SGD","LU1861220033.SGD","LU0566484027.USD","CORT","LU0048573561.USD","WFC","BK4613","LU0256863811.USD","LU0868494617.USD","LU1988902786.USD","IE00B894F039.SGD","LU1069347547.HKD","LU0310800379.SGD","LU1267930573.SGD","BK4182","IE00BZ9MQY76.HKD","BK4564","IE000M9KFDE8.USD","LU0056508442.USD","LU0648001328.SGD","LU1235294995.USD","LU0106831901.USD","LU1506573853.SGD","LU0251131958.USD","BK4501"],"gpt_icon":1},{"id":"2592183246","title":"These Stock Funds Are Crushing the Market. Here Are Their Picks for 2026. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2592183246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592183246?lang=en_us&edition=fundamental","pubTime":"2025-12-19 01:19","pubTimestamp":1766078340,"startTime":"0","endTime":"0","summary":"It isn't easy for stock fund managers to beat the market. When they do, you might want to listen to what they say.With the S&P 500 index up 16% in 2025, keeping pace has been difficult for funds that didn't own large helpings of stocks leading the charge: tech giants like Nvidia, Broadcom, and Alphabet.Yet a handful of funds are beating the market. And some of the winning managers have found ways to thrive beyond tech, emphasizing stocks in sectors such as industrials, materials, and healthcare.Barron's recently connected with three fund managers who delivered some of the best returns this year, through Nov. 30. We wanted to find out how they did it and, more importantly, where they see bargains for 2026.With just $31 million in assets, Tanaka Growth flies under the radar. It may be time to pay attention. The fund is up nearly 50% this year and returned 22.4% over the last five years on an annualized basis, beating 99% of rivals, according to Morningstar.\"They've got 10 years of growth","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0097036916.USD","LU0106831901.USD","LU1064131342.USD","IE00BZ9MQY76.HKD","LU1861215975.USD","LU1506573853.SGD","LU0029864427.USD","LU1074936037.SGD","LU1791807156.HKD","LU2360106780.USD","LU0211327993.USD","LU2298322129.HKD","BK4588","LU0683600562.USD","LU2361044949.HKD","LU0124384867.USD","LU0971096721.USD","LU1069347547.HKD","IE0002270589.USD","LU0130517989.USD","LU0708994859.HKD","BK4504","LU2065171402.SGD","LU2294711713.HKD","LU0868494708.USD","LU0476273544.USD","LU0742534661.SGD","LU0823414551.USD","LU1852331112.SGD","BK4585","BK4512","LU1988902786.USD","BK4539","LU1668664300.SGD","LU2361045086.USD","LU0648001328.SGD","LU0823414478.USD","LU0640476718.USD","LU0251142724.SGD","IE00B19Z9P08.USD","LU2065169927.USD","BK4182","LU0149725797.USD","BK4532","IE0004091025.USD","LU0175139822.USD","LU0444971666.USD","LU1815336760.USD","BK4559","BK4023","LU1861220033.SGD","LU0942090050.USD","LU2236285917.USD","LU1642822529.SGD","LU0130102774.USD","LU1267930573.SGD","LU0566484027.USD","LU1978683503.SGD","LU0070302665.USD","LU0314106906.USD","LU0081259029.USD","LU2087625088.SGD","LU1093756168.USD","LU0056508442.USD","LU0868494617.USD","LU0320765489.SGD","LU0256863811.USD","IE0004086264.USD","LU1267930490.SGD","LU1823568750.SGD","BK4608","LU2506951792.HKD","LU0128525689.USD","LU1363072403.SGD","LU2098885051.SGD","LU0417517546.SGD","LU1201861249.SGD","LU2264538146.SGD","LU0477156953.USD","LU0006061336.USD","CORT","APP","BK4613","LU2357125470.USD","LU2461242641.AUD","LU0310800379.SGD","LU0724618433.USD","IE00B19Z9Z06.USD","LU0267386448.USD","IE000M9KFDE8.USD","LU2290526834.HKD","LU2065171311.SGD","LU0957808578.USD","LU2065170008.USD","LU0052756011.USD","LU0251131958.USD","GB00BDT5M118.USD","LU1235294995.USD","LU0444973449.USD","LU1814569148.SGD","LU0310799852.SGD","IE00B7SZLL34.SGD","LU2360107168.USD","LU0208291251.USD","BK4007","WFC","LU1303367103.USD","IE00B19Z3B42.SGD","LU0353189763.USD","LU0787776722.HKD","LU0048573561.USD","LU0211328371.USD","LU1046421795.USD","LU1559883803.SGD","LU0353189680.USD","LU1093756325.SGD","BK4501","LU0310800965.SGD","IE00B19Z3581.USD","LU0980610538.SGD","LU1280957306.USD","LU1267930227.SGD","LU0162691827.USD","LU1035773651.USD","LU2361044865.SGD","WDC","LU0072461881.USD","IE00B894F039.SGD","LU0128525929.USD","LU2063271972.USD","LU0289960550.SGD","LU0154236417.USD","BK4207","LU2249611893.SGD","BK4170","LU2250418816.HKD"],"gpt_icon":1},{"id":"2592932836","title":"Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932836?lang=en_us&edition=fundamental","pubTime":"2025-12-17 03:55","pubTimestamp":1765914900,"startTime":"0","endTime":"0","summary":"1454 ET - Corcept Therapeutics isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2592931338","title":"Oil Prices Sink To $55, Lowest In Nearly 5 Years: What's Moving Markets Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931338","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931338?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:47","pubTimestamp":1765907254,"startTime":"0","endTime":"0","summary":"Wall Street lacked clear direction on Tuesday, as mixed labor market data failed to ignite a fresh wave of risk-on sentiment.","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2025/12/16/Oil-prices-crash.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2025/12/16/Oil-prices-crash.jpeg"],"rights":{"source":"Benzinga","url":"https://www.benzinga.com/markets/equities/25/12/49429308/markets-today-tuesday-wall-street-oil-drops-to-5-year-lows-jobs-report-november","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49429308/markets-today-tuesday-wall-street-oil-drops-to-5-year-lows-jobs-report-november","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["LU0289739343.SGD","DOG",".IXIC","CORT","USAW.SI","AMKR","LU0106831901.USD","BAH","LU0012050646.USD","FDN","RH","PSQ","BK4106","AFRM","VOO","SDOW","BK4227","MYMmain","BK4020","BK4588","BK4532","LU1861220033.SGD","QQQ","NVIW.SI","BK4550","MNQmain","UDOW","NQmain","BK4178","TQQQ","LU0240878834.USD","QID","USJW.SI","DJX","DXD","QLD","DDS","SQQQ","DDM","TSYW.SI","BK4157","LU0205193047.USD","GLIBA","CGNX","LU0289961442.SGD","LU0511384066.AUD","LU1668664300.SGD",".DJI"],"gpt_icon":1},{"id":"2591793592","title":"UBS Initiates Corcept Therapeutics at Neutral With $95 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2591793592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591793592?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:49","pubTimestamp":1765900192,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) has an average rating of overweight and mean price target of $127.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"gpt_icon":0},{"id":"2591382189","title":"Corcept Therapeutics Inc : UBS Initiates Coverage With Neutral Rating and Target Price  $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2591382189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591382189?lang=en_us&edition=fundamental","pubTime":"2025-12-16 22:46","pubTimestamp":1765896389,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nAZN4RFU2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU0566484027.USD","BK4007","CORT","LU1559883803.SGD"],"gpt_icon":0},{"id":"2591123987","title":"Corcept Therapeutics Initiated at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2591123987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591123987?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:49","pubTimestamp":1765892940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 08:49 ET (13:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2588076560","title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588076560","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588076560?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:15","pubTimestamp":1764810909,"startTime":"0","endTime":"0","summary":"Joseph K. Belanoff, Chief Executive Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL37zBvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","BK4532","BK4007","CORT"],"gpt_icon":0},{"id":"2587308397","title":"Corcept Therapeutics (CORT): Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2587308397","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587308397?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:21","pubTimestamp":1764361266,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) has adjusted its revenue outlook for 2025, citing capacity constraints with a previous specialty pharmacy vendor. This adjustment comes as new prescriptions for Korlym continue to increase in its hypercortisolism segment.\nSee our latest analysis for Corcept Therapeutics.\nCorcept’s revenue guidance revision comes after strong momentum in both its core business and share price. Despite recent insider selling and mixed third-quarter results, the stock has delivered a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-assessing-valuation-after-revenue","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-assessing-valuation-after-revenue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2586293250","title":"Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586293250","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586293250?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:23","pubTimestamp":1764195821,"startTime":"0","endTime":"0","summary":"William Guyer, Chief Development Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL7shfDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","LU0566484027.USD","BK4007","BK4532","LU1559883803.SGD"],"gpt_icon":0},{"id":"2586204904","title":"Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2586204904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586204904?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:14","pubTimestamp":1764072840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 07:14 ET (12:14 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2581834048","title":"Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834048","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581834048?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:10","pubTimestamp":1762553437,"startTime":"0","endTime":"0","summary":"William Guyer, Chief Development Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of Corcept Therapeutics Incorporated. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5LlC8V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","BK4007","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2581840670","title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581840670","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581840670?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:58","pubTimestamp":1762390711,"startTime":"0","endTime":"0","summary":"Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7Hsg4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","BK4532","LU0566484027.USD","LU1559883803.SGD"],"gpt_icon":0},{"id":"2581084062","title":"Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Corcept Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084062","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581084062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:57","pubTimestamp":1762390635,"startTime":"0","endTime":"0","summary":"Sean Maduck, Officer at Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1TSLC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Corcept Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","LU0566484027.USD","LU1559883803.SGD","BK4532"],"gpt_icon":0},{"id":"2581743667","title":"H.C. Wainwright Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581743667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581743667?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:56","pubTimestamp":1762358183,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics today and set a price target of $145.00. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"1184309320","title":"Stock Track | Corcept Therapeutics Soars 5.61% as Analyst Maintains Buy Rating Amid Recent Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184309320","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184309320?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:29","pubTimestamp":1762356599,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (CORT) surged 5.61% in Wednesday's pre-market trading session, rebounding from a recent pullback as investors reacted to positive analyst sentiment and reassessed the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581727938","title":"Truist Financial Sticks to Their Buy Rating for Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727938?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:57","pubTimestamp":1762347451,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Corcept Therapeutics today. The company’s shares closed yesterday at $71.10. Lee cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"1149507846","title":"Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1149507846","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149507846?lang=en_us&edition=fundamental","pubTime":"2025-11-05 17:22","pubTimestamp":1762334549,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581872525","title":"Does Corcept Therapeutics’ Recent 21% Pullback Signal a Fresh Opportunity in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581872525","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581872525?lang=en_us&edition=fundamental","pubTime":"2025-11-05 15:46","pubTimestamp":1762328772,"startTime":"0","endTime":"0","summary":"Wondering if Corcept Therapeutics is still a smart buy or if the market has gotten ahead of itself? If you’re curious about getting real value from your investments, this could be the stock to watch.\nThe past year has been good to Corcept, with the stock climbing 31.1% over 12 months and an eye-catching 42.3% year to date. However, recent weeks have seen a pullback of -20.9% for the month and -1.3% in the past week.\nThese price swings come as a result of heightened investor attention, driven...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-recent-21-pullback-signal-a-fresh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-recent-21-pullback-signal-a-fresh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1559883803.SGD","BK4007","CORT","DCF","BK4532","LU0566484027.USD"],"gpt_icon":0},{"id":"1156587177","title":"Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1156587177","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156587177?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:16","pubTimestamp":1762305405,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0481},{"period":"1month","weight":0.1007},{"period":"3month","weight":0.0402},{"period":"6month","weight":0.1734},{"period":"1year","weight":0.6375},{"period":"ytd","weight":0.6622}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.016463},{"month":2,"riseRate":0.428571,"avgChangeRate":0.014054},{"month":3,"riseRate":0.761905,"avgChangeRate":0.141286},{"month":4,"riseRate":0.52381,"avgChangeRate":-0.001402},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.454545,"avgChangeRate":0.055477}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction